Arrowhead Pharmaceuticals Initiates Phase II GATEWAY Study of Investigational ARO-ANG3 for Treatment of Homozygous Familial Hypercholesterolemia

Arrowhead Pharmaceuticals Inc. announced that it has dosed the first patients in the Phase II GATEWAY clinical study of investigational ARO-ANG3 for the treatment of patients with homozygous familial hypercholesterolemia.